![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JA Auchampach, M Maruyama, I Cavero and GJ Gross
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee.
The objective of the present study was to determine the effect of a novel K+ channel opener, Aprikalim (RP 52891; [trans-(-)-N-methyl-2-(3- pyridyl)-2-tetrahydrothio-pyran carbothiamide-1-oxide]), on myocardial infarct size in barbital-anesthetized dogs subjected to 90 min of left circumflex coronary artery occlusion followed by 5 hr of reperfusion. To determine if RP 52891 is mediating its effects by opening adenosine triphosphate regulated potassium channels (KATP), glibenclamide, a KATP channel antagonist was used. Dogs were pretreated with vehicle, a nonhypotensive dose of RP 52891 (10 micrograms/kg + 0.1 microgram/kg/min i.v.), glibenclamide (1 mg/kg; i.v. bolus) or RP 52891 (10 micrograms/kg and 0.1 microgram/kg/min i.v.) after pretreatment with glibenclamide (1 mg/kg i.v. bolus). At the end of reperfusion, myocardial infarct size was determined by triphenyltetrazolium staining. There were no significant differences in systemic hemodynamics, myocardial oxygen demand, collateral blood flow or ischemic bed size among groups with the exception of an increase in coronary blood flow to the ischemic area at 3 and 5 hr of reperfusion in both RP-treated groups. However, myocardial infarct size, expressed as a percentage of the area at risk, was significantly (P less than .05) reduced (38%) by RP 52891 and significantly increased (38%) by glibenclamide (vehicle, 39 +/- 4%; RP 52891, 24 +/- 2%; and glibenclamide, 54 +/- 5%).(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  G. J. Grover, A. J. D'Alonzo, R. B. Darbenzio, C. S. Parham, T. A. Hess, and M. S. Bathala In Vivo Characterization of the Mitochondrial Selective KATP Opener (3R)-trans-4-((4-Chlorophenyl)-N-(1H-imidazol-2-ylmethyl)dimethyl-2H-1-benzopyran-6-carbonitril Monohydrochloride (BMS-191095): Cardioprotective, Hemodynamic, and Electrophysiological Effects J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 132 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Grover, A. J. D'Alonzo, K. D. Garlid, R. Bajgar, N. J. Lodge, P. G. Sleph, R. B. Darbenzio, T. A. Hess, M. A. Smith, P. Paucek, et al. Pharmacologic Characterization of BMS-191095, a Mitochondrial KATP Opener with No Peripheral Vasodilator or Cardiac Action Potential Shortening Activity J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1184 - 1192. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. A. Ockaili, P. Bhargava, and R. C. Kukreja Chemical preconditioning with 3-nitropropionic acid in hearts: role of mitochondrial KATP channel Am J Physiol Heart Circ Physiol, May 1, 2001; 280(5): H2406 - H2411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Monti, K. Iwashiro, S. Picard, A. Criniti, S. La Francesca, G. Ruvolo, U. Papalia, P. P. Campa, B. Marino, and P. E. Puddu ADENOSINE TRIPHOSPHATE-DEPENDENT POTASSIUM CHANNEL MODULATION AND CARDIOPLEGIA-INDUCED PROTECTION OF HUMAN ATRIAL MUSCLE IN AN IN VITRO MODEL OF MYOCARDIAL STUNNING J. Thorac. Cardiovasc. Surg., April 1, 2000; 119(4): 842 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Schotborgh and A. A.M. Wilde ATP-Sensitive Potassium Channel Openers and Blockers in the Cardiovascular System: Physiology, Pharmacology, and Clinical Effects Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 243 - 255. [Abstract] [PDF]
|
|
|
|
|
|
A. W. Gomoll, R. A. Roth, R. E. Swillo, A. J. Baird, C. S. Sargent, R. W. Behling, H. J. Malone, and G. J. Grover Effect of Timing of Treatment of the Glyburide-Reversible Cardioprotective Activity of BMS-180448 J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 24 - 33. [Abstract] [Full Text]
|
|
|
|
|
|
G. J. Gross, D. A. Mei, P. G. Sleph, and G. J. Grover Adenosine A1 Receptor Blockade Does Not Abolish the Cardioprotective Effects of the Adenosine Triphosphate-sensitive Potassium Channel Opener Bimakalim J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 533 - 540. [Abstract] [Full Text]
|
|
|
|
|
|
J. R. Lopez, R. Jahangir, A. Jahangir, W. K. Shen, and A. Terzic POTASSIUM CHANNEL OPENERS PREVENT POTASSIUM-INDUCED CALCIUM LOADING OF CARDIAC CELLS: POSSIBLE IMPLICATIONS IN CARDIOPLEGIA J. Thorac. Cardiovasc. Surg., September 1, 1996; 112(3): 820 - 831. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
